Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 10/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.44 |
| ▸ | GALR3 | O60755 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1105181 | 0.96 | NOTUM (0.65) | NOTUMMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL12201981 | 0.89 | NOTUM (0.65) | NOTUMMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL12201982 | 0.87 | NOTUM (0.58) | NOTUMMEN1KMT2APOLBHPGD | |
| SCHEMBL12201990 | 0.82 | NOTUM (0.60) | NOTUMMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL1123774 | 0.80 | NOTUM (0.57) | NOTUMMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL1105179 | 0.79 | CYP2C9 (0.57) | NOTUMMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL12202001 | 0.78 | NOTUM (0.61) | NOTUMMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL13763889 | 0.74 | NOTUM (0.61) | NOTUMPOLBLMNAMAPTGALR3 | |
| SCHEMBL20353537 | 0.74 | ALDH1A1 (0.65) | MEN1KMT2APOLBALDH1A1HPGD | |
| SCHEMBL12201999 | 0.72 | NOTUM (0.67) | NOTUMPOLBALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034943-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-8034943-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-20100137364-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137364-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7671205-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671205-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070173530-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173530-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137364-A1 | 6-Aminoisoquinoline Compounds | COQ8A, PGC, AGK | NOTUM 3635/4885MEN1 3210/4885KMT2A 2030/4885 |
| US-20070173530-A1 | 6-Aminoisoquinoline Compounds | COQ8A, PGC, AGK | NOTUM 3635/4885MEN1 3210/4885KMT2A 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.